RAS Dialogue
Join the discussion! Post comments, ask questions, and share information with RAS experts. Subscribe to receive notifications when a new RAS Dialogue article is posted.
-
SOS signaling in RAS-mutated cancersSOS proteins participate in controlling the activity of the RAS pathway, even when RAS itself is mutated and driving cancer. Inhibitors of SOS in combination with other drugs show promise as elements of new cancer therapies.
-
RAS Mutation TropismThe three isoforms of Ras share signaling modalities, yet their cancer-associated mutations vary widely in sequence and the organs affected. Sequencing those mutations very soon after they occur sheds light on the forces driving those differences.
-
The disease burden of RasCancer genome databases yield different estimates of the importance of RAS genes in cancers. Integrating the data that underlie those estimates may suggest new research priorities based on patient numbers.
-
Alternative cells-of-origin influence the heterogeneity of KRAS-mutant lung adenocarcinomaThe biology of lung cancers driven by mutant KRAS is substantially influenced by the particular cell type in which the KRAS mutation arose. Understanding how the cell of origin and its surroundings react to mutant KRAS suggest therapeutic approaches.
-
The RASopathies NetworkRASopathies are neurodevelopmental genetic syndromes caused by germline mutations in RAS pathway genes that result in increased MAPK signaling. The RASopathies Network provides an umbrella organization to connect affected families with researchers.